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Emergence of drug resistance and adverse effects often affect the efficacy of 
nucleoside analogues in the therapy of Herpes simplex type 1 (HSV-1) and type 2 (HSV-2) 
infections. Host-targeting antivirals could therefore be considered as an alternative or 
complementary strategy in the management of HSV infections. To contribute to this 
advancement, here we report on the ability of a new generation inhibitor of a key cellular 
enzyme of de novo pyrimidine biosynthesis, the dihydroorotate dehydrogenase (DHODH), 
to inhibit HSV-1 and HSV-2 in vitro replication, with a potency comparable to that of the 
reference drug acyclovir. Analysis of the HSV replication cycle in MEDS433-treated cells 
revealed that it prevented the accumulation of viral genomes and reduced late gene 
expression, thus suggesting an impairment at a stage prior to viral DNA replication 
consistent with the ability of MEDS433 to inhibit DHODH activity. In fact, the anti-HSV 
activity of MEDS433 was abrogated by the addition of exogenous uridine or of the product 
of DHODH, the orotate, thus confirming DHODH as the MEDS433 specific target in HSV-
infected cells. A combination of MEDS433 with dipyridamole (DPY), an inhibitor of the 
pyrimidine salvage pathway, was then observed to be effective in inhibiting HSV 
replication even in the presence of exogenous uridine, thus mimicking in vivo conditions. 
Finally, when combined with acyclovir and DPY in checkerboard experiments, MEDS433 
exhibited highly synergistic antiviral activity. Taken together, these findings suggest that 
MEDS433 is a promising candidate as either single agent or in combination regimens with 
existing direct-acting anti-HSV drugs to develop new strategies for treatment of HSV 
infections. 
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biosynthesis; Dihydroorotate dehydrogenase; Salvage pathway; Combination treatment.  
 









The Herpes simplex virus (HSV) type 1 (HSV-1) and type 2 (HSV-2) causes lifelong 
infections characterized by periodic reactivations at the site of primary infection, and 
globally widespread among human populations with a seroprevalence of 50% to 90% in 
adults. HSV-1 is traditionally associated with orofacial lesions and encephalitis, while HSV-
2 is associated with genital diseases, although both oral HSV-2 infections and genital 
herpes caused by HSV-1 are recognized with increasing frequency. Following primary 
infection, HSV establishes latent infections in the neurons of the sensory ganglia from 
where they may, or may not, reactivate, causing recurrent infections (Roizman et al., 
2013). 
HSV infections are associated to a wide range of clinical manifestations that diversify from 
asymptomatic infection or mild mucocutaneous lesions on the lips, cornea, genitals, or 
skin, to more severe diseases, such as encephalitis and recurrent keratitis, and up to even 
life-threatening systemic disseminate infections in immunocompromised patients or 
neonates after perinatal transmission (Roizman et al., 2013, Whitley, 2015; Samies and 
James, 2020).  
Even if HSV infections are often subclinical, their incidence and the severity of diseases 
have increased over the past decades due mainly to the increasing number of transplant 
recipients. Concurrently, genital herpes has become one of the world’s most prevalent 
sexually transmitted infections with evidence suggesting that HSV-2 infection increases 
the risk of acquiring HIV (Looker et al., 2017). Together the worldwide burden of HSV 
diseases is significant, as in 2016 3,7 billion of HSV-1 infections and about half a billion of 
HSV-2 infections have been estimated by WHO (James et al., 2020). 
Treatment of symptomatic primary or recurrent HSV infections with nucleoside 
analogues, such as acyclovir (ACV), famciclovir (FAM), and valacyclovir (VCV) that act as 
viral DNA polymerase inhibitors, ensure an effective therapeutic management of most 









infection, and their extensive clinical use may lead to treatment failures due to the 
development of drug resistance, and to adverse effects mainly deriving from long-term 
toxicity (Whitley and Baines, 2018). 
Taking into consideration both these limitations and the absence of efficacious vaccines, 
the treatment of HSV infections remains a high priority and highlights the need for the 
development of new antiviral agents directed against new targets. To this regard, host-
targeted small molecules able to modulate virus-host interactions may be considered a 
compelling alternative to the de novo development of virally targeted agents, for which the 
typical timeline for approval can require more than 10 years. 
Pyrimidines availability in infected cells is crucial for virus replication and thus 
compounds targeting the de novo pyrimidine biosynthetic pathway have the potential to be 
validated as host-acting antiviral (HTA) agents (Okesli et al., 2017). Furthermore, in 
addition to the advantage of overcoming viral drug resistance, inhibitors of pyrimidine 
biosynthesis, given the independence of the antiviral effects with respect to a specific virus 
replication strategy, may be broadly deployed against viruses belonging to different 
families, thus developed as broad-spectrum antivirals (BSAs) (Okesli et al., 2017). In the 
de novo pyrimidine biosynthesis pathway, the dihydroorotate dehydrogenase (DHODH) 
catalyzes the rate-limiting step of dehydrogenation of dihydroorotate (DHO) to orotate 
(ORO), essentially providing uridine and cytidine to fulfill cellular nucleotides demand (Reis 
et al., 2017; Loeffler et al., 2020). Therefore, due to its critical role in the biosynthetic 
pathway, DHODH is currently considered as a host target of choice for anti-infective drug 
development (Okesli et al., 2017; Boschi et al., 2019). 
Recently, we have identified a novel class of human DHODH (hDHODH) inhibitors 
characterized by an unusual carboxylic group bioisostere 2-hydroxypyrazolo[1,5a] 
pyridine (Sainas et al., 2018) that had been designed on the scaffold of brequinar, one of 









showed little, if any, toxicity for human normal cells, while they induced myeloid 
differentiation in Acute Myeloid Leukemia (AML) cell lines through hDHODH inhibition, and 
therefore they are further being developed for treatment of AML (Sainas et al., 2018; 
Sainas et al., 2020). 
The aim of this study was to investigate the potential of deploying this new class of 
hDHODH inhibitors against HSV-1 and HSV-2. We report on the ability of one of these 
small molecules, named MEDS433, to potently inhibit the in vitro replication of HSV-1 and 
HSV-2 via a mechanism that stems from selective blocking the DHODH enzymatic activity. 
These results indicate MEDS433 as a promising candidate as either single agent or as 
combination regimens, to develop new strategies for treatment of HSV infections. 
 
2. Materials and Methods 
2.1 Compounds 
MEDS433 and the small library of hDHODH inhibitors (Table 1) based on a hydroxyazole 
scaffold, were synthesized as described previously (Sainas et al., 2018; Sainas et al., 
2021). Acyclovir (ACV), uridine (UR), orotic acid (ORO), dihydroorotic acid (DHO), and 
dipyridamole (DPY) were purchased from Sigma-Aldrich. All compounds were 
resuspended in DMSO. 
2.2 Cells and viruses 
African green monkey kidney cells (Vero) (ATCC CCL-81) and the human glioblastoma 
astrocytoma U-373 MG cell line (ATCC HTB-17) were purchased from the American Type 
Culture Collection (ATCC) and cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Euroclone) supplemented with 10% fetal bovine serum (FBS, Euroclone), 2 mM glutamine, 
1 mM sodium pyruvate, 100 U/ml penicillin, and 100 μg/ml streptomycin sulfate (P/S, both 
from Euroclone). Clinical isolates of HSV-1 (AS1 and AS2) and HSV-2 (AS3 and AS4) 









Italy. They were propagated and titrated by plaque assay on Vero cells, as previously 
described (Luganini et al., 2011; Terlizzi et al., 2016) 
2.3 Citotoxicity assay  
Vero cells were seeded in 96-well plates (15000 cells/well) and after 24 h the cells were 
exposed to increasing concentrations of compounds or vehicle (DMSO), as control. After 
72 h of incubation, the number of viable cells was determined using the CellTiter-Glo 
Luminescent assay (Promega) according to the specifications of the manufacturer. 
2.4 Antiviral assays 
To screen the mini-library of hDHODH inhibitors, plaque reduction assays (PRAs) were 
performed with Vero cells seeded in 24-well plate (50000 cells/well) and then treated with 
a single dose (0.5 μM) of the different compounds 1 h prior to and during infection with the 
clinical isolate of HSV-1 AS1 at 50 PFU/well. Following virus adsorption (2 h at 37 °C), 
viral inocula were removed, and cells were maintained in medium containing the 
corresponding compounds, 3% FBS, and 0.9% methylcellulose. After 48 h post-infection 
(p.i.) cell monolayers were fixed, stained with crystal violet, and viral plaques were 
microscopically counted; the mean plaque counts for each drug concentration were 
expressed as a percentage of the mean plaque counts of control virus (DMSO).  
To evaluate the anti-HSV activity of selected compound, virus yield reduction assay (VRA) 
were performed on Vero cells, as previously described (Luganini et al., 2011; Terlizzi et al., 
2016). For VRA, both untreated cells and those incubated with different concentrations of 
MEDS433 for 1 h before infection were infected with the clinical isolates HSV-1 and HSV-2 
at a multiplicity of infection (MOI) of 0.01 or 1 PFU/cell. Following virus adsorption (2 h at 
37°C), cultures were maintained in medium containing compounds and then incubated for 
48 h p.i. until control cultures displayed extensive cytopathology. Thereafter, the cells and 
supernatants from the antiviral assay were harvested and disrupted by sonication. The 








cell suspensions on Vero cells. The mean plaque counts for compounds were expressed 
as a percentage of the mean plaque counts for the control virus (DMSO-treated), and the 
concentration that produced a 50% and 90% of reduction in plaque formation (EC50 and 
EC90) was determined by GraphPad Prism software. 
To evaluate the effect of uridine, DHO or ORO addition, PRAs were performed with Vero 
cells infected with HSV-1 AS1 or HSV-2 AS3 (50 PFU/well), and treated with increasing 
concentrations of uridine, ORO or DHO (10, or 100, or 1000 μM) in presence of 1 μM of 
MEDS433. After 48 h p.i., cell monolayers were fixed, stained with crystal violet, and 
plaques microscopically counted. To investigate the effect of blocking both the de novo 
biosynthesis and the salvage pathway of pyrimidines, Vero cells were infected with HSV-1 
AS1 or HSV-2 AS3 (50 PFU/well) and treated throughout PRAs with different 
concentration of MEDS433 in combination with increasing concentrations of dipyridamole 
(0.5, 1.5 and 3 μM) in media supplemented with concentrations of uridine (20 μM) that 
exceed the physiological uridine plasma levels ranging from 2 to 6 μM (Pizzorno, et al. 
2002).  
At 48 h p.i., cell monolayers were fixed, stained and plaques microscopically counted. 
To assess the effects of the combination of MEDS433 and ACV or MEDS433, ACV and 
DPY on HSV-1 AS1 replication, PRAs were performed as described above. MEDS433 and 
ACV, as single agents or in combination, were added on Vero cells at equipotent ratio of 
0.25 x, 0.5 x, 1 x, 2 x and 4 x the EC50 of each drug. For the three-drug combination, DPY 
(3 μM) was added to the MEDS433 and ACV concentrations used in the two-drug 
combination. The effect of the two- or three-drug combinations was then assessed using 
the Chou-Talalay method (Chou, 2006) based on the median-effect principle of the mass-
action law computed in the CompuSyn software (http://www.combosyn.com)(Chou and 
Martin, 2005). With the Chou-Talalay method, a Combination Index (CI) = 1 represents an 









2.5 Quantitative real-time PCR 
Vero cells were seeded in a 6-well plate (600000 cells/well) and, after 24 h, treated with 5 
μM MEDS433 1h prior to and during infection with the clinical isolate of HSV-1 AS1 at a 
multiplicity of infection (MOI) of 0.1 PFU/cell. At different times p.i., cells were harvested 
and DNA was extracted and purified using a DNA purification kit (Zymo Research). The 
levels of viral DNA were then evaluated by quantitative real-time PCR using a GENESIG 
standard kit (Primerdesign) to amplify a segment of the DNA polymerase UL30 gene. 
Briefly, 25 ng of DNA from each sample was amplified in triplicate using PrecisionPlus Low 
ROX qPCR master mix (Primerdesign), the oligonucleotide primers and the TaqMan UL30 
probe, dually labeled (5′, fluorescein 6-carboxyfluorescein [FAM]; 3′, Iowa Black® dark 
quencher). After activation of Hot Start Taq DNA polymerase for 2 min at 95 °C, samples 
underwent 45 cycles of 10 s at 95 °C and 1 min at 60 °C in a QuantStudio3 real-time PCR 
(Applied Biosystem). For HSV genome copy number determination, a serially diluted 
UL30-encoding plasmid (GENESIG standard kit) was used to determine a standard curve 
for mean Ct values and to calculate HSV genome copy numbers. 
2.6 Immunoblotting 
Vero cells were seeded in 6-well plates (600000 cells/well) and, after 24 h, were treated 
with 5 μM of MEDS433 1 h prior to and during infection with HSV-1 AS1 at a MOI of 1 
PFU/cell. Whole-cell extracts were prepared at different times p.i., as previously described 
(Luganini et al., 2008, Mercorelli et al., 2016). An equal amount of the cell extracts was 
fractionated by 8% SDS-PAGE and then transferred to PVDF membranes (BioRad). Filters 
were blocked for 2 h at 37 °C in 5% non-fat dry milk in 10 mM Tris-HCl (pH 7.5), 100 mM 
NaCl, and 0.05% Tween 20 and immunostained with the mouse anti-HSV-1 ICP27 mAb 
(clone H1113; Virusys) (diluted 1:500), anti-HSV-1 ICP5 mAb (clone 3B6; Virusys) (diluted 
1:500), or with anti-tubulin mAb (Chemicon International) (diluted 1:2000) as a control for 








conjugated to horseradish peroxidase (Life Technologies) and visualized by enhanced 
chemiluminescence (Western Blotting Luminol Reagent, Santa Cruz). 
2.8 Statistical Analysis 
All statistical tests were performed using GraphPad Prism version 7.0. Antiviral assays 
data are presented as the means ± SDs of at least three experiments performed in 
triplicate. Differences were considered to be statistically significant for p<0.05. 
 
3. Results 
3.1 Inhibition of HSV-1 and HSV-2 replication by the DHODH inhibitor MEDS433  
To generate new hDHODH inhibitors, we have recently applied a rational modulation to 
brequinar, one of the most potent hDHODH inhibitors so far discovered (Peters et al., 
2018). A combination of structure-based and bioisosterism (Sainas et al, 2019) 
approaches resulted in a series of new 2-hydroxypyrazolo[1,5-a]pyridine derivatives of 
brequinar (Sainas et al., 2018; Sainas et al., 2021). Here, to investigate the feasibility of 
targeting DHODH activity to develop HTA aimed at inhibiting HSV replication, 9 of these 
new hDHODH inhibitors (Table 1) were selected using plaque reduction assays in which 
test compounds were present before, during and after virus infection. As shown in Fig. 1A, 
when tested at 0.5 µM, five compounds (1, 4, 5, 7, and MEDS433) were able to decrease 
HSV-1 AS1 replication of more than 50%, while the remaining four compounds (2, 3, 6 and 
8), reduced the virus replication of about 20-30%. Since MEDS433 was the most effective 
hDHODH inhibitor against HSV-1 replication (Fig. 1), it was selected for further analysis. 
Virus yield reduction assays (VRAs) then confirmed a significant concentration-dependent 
inhibition of virus replication in Vero cells treated with MEDS433, and infected with the 
clinical isolates HSV-1 AS1 or HSV-2 AS3 at a multiplicity of infection (MOI) of 0.01 or 1 








indicated that the inhibitory effect of MEDS433 cannot be overcome by infecting cells at 
higher multiplicities of infection.  
To further strengthen these observations, a second pair of clinical isolates of HSV-1 and 
HSV-2, respectively HSV-1 AS2 and HSV-2 AS4, was examined by VRAs. As reported in 
Table 2, MEDS433 was effective also against HSV-1 AS2 and HSV-2 AS4, thus indicating 
that the anti-HSV activity of MEDS433 was independent from the viral strain used, and 
sustaining the view that indeed it targeted a host pathway in HSV-infected cells. 
Nevertheless, the antiviral activity of MEDS433 was not due to cytotoxicity of the target 
cells themselves, since the Cytotoxic Concentration (CC50) determined in uninfected Vero 
cells was 234 ± 18.2 μM, with a favorable Selective Index (SI) on average greater than 
2,100 and 3,000 for HSV-1 and HSV-2, respectively.  
Noteworthy, MEDS433 showed an anti-HSV activity (Table 2) at least comparable to that 
of the reference drug ACV (EC50 0.280 ± 0.080 and 0.120 ± 0.042 μM against HSV-1 AS1 
and HSV-2 AS3, respectively), while it was more effective than the reference hDHODH 
inhibitor brequinar (EC50 0.420 ± 0.124 μM against HSV-1 AS1 and 1.250 ± 0.276 μM 
against HSV-2 AS3, respectively).  
Furthermore, in addition to being MOI-independent, the anti-HSV activity of MEDS433 was 
also cell-type independent, as it was observed in the human glioblastoma astrocytoma U-
373 MG cell line permissive for HSV replication (Andrei et al., 1994). In these cells of 
neural origin, MEDS433 in fact inhibited HSV-1 AS1 replication with EC50 and EC90 values 
of 0.297 ± 0.080 and 1.881 ± 0.487 μM, respectively.   
As a whole, these results indicate a potent anti-HSV activity of MEDS433 independent of 
the virus strain, the MOI, or the cell type used. 
 









To get more insights into the nature of the antiviral activity of MEDS433, we 
investigated its effects on HSV-1 DNA synthesis at different times p.i.. As reported in Fig. 
3, in untreated HSV-1-infected Vero cells, the qPCR analysis measured a progressive 
increase of viral DNA levels up to 48 h p.i.. Conversely, the MEDS433 treatment 
determined an impairment of HSV-1 DNA synthesis starting from 16 h p.i. and for the 
entire time frame that was evaluated, thus suggesting that it can target the HSV replication 
cycle at a stage prior to the onset of viral DNA replication.  
To further supporting this hypothesis, total protein extracts were prepared at various times 
p.i. from HSV-1-infected Vero cells treated with MEDS433 and the content of ICP27 and 
ICP5 proteins was evaluated to monitor the levels of representative immediate-early (IE) 
and late (L) HSV protein expression, respectively. As seen in Fig. 4, compared to cells 
treated with the vehicle DMSO, MEDS433 treatment did not affect noticeably the 
expression of ICP27 protein accumulation at any time analyzed. In contrast, it determined 
a clear reduction of the late ICP5 protein levels at 12 and 24 h p.i..  
Together, these results suggest that MEDS433 targets HSV replication cycle after the 
expression of IE proteins and likely interferes with the viral DNA synthesis, since the 
MEDS433-mediated inhibition at this stage (Fig. 3) reduces late gene expression (Fig. 4). 
 
3.3 The pyrimidine biosynthesis pathway is involved in the anti-HSV activity of MEDS433  
The above results suggest a mechanism of the anti-HSV activity of MEDS433 
consistent with its ability to inhibit DHODH activity. To verify this hypothesis, we 
investigated whether the antiviral HSV activity of MEDS433 could be overcome by the 
addition of increasing concentrations of exogenous uridine. As shown in Fig. 5, the 
inhibitory effect of 1 μM MEDS443 on both HSV-1 (Fig. 5A) and HSV-2 (Fig. 5B) 
replication was significantly reversed by a 10-fold excess of uridine relative to MEDS433 









restored HSV replication, thus indicating that the pyrimidine pathway was affected by 
MEDS433. Then, to confirm that DHODH inhibition by MEDS433 was responsible of its 
anti-HSV effect, cell medium was supplemented with increasing concentrations of the 
substrate dihydroorotic acid (DHO) or the DHODH product, orotic acid (ORO). In HSV-
infected Vero cell cultures treated with MEDS433 (1 μM), the addition of orotic acid 
reversed significantly the inhibitory effect of MEDS433 on HSV-1 and HSV-2 replication 
already at a concentration 10-fold that of MEDS433 (Fig. 5, lower panels). However, the 
reverting effect of orotic acid to MEDS433 was almost complete at the highest 
concentration (1000 x the MEDS433 concentration) evaluated. In contrast, the addition of 
DHO even at 1 mM (1000 times more than MED433) did not affect the anti-HSV activity of 
MEDS433 (Fig.5, lower panels), thus indicating that MEDS433 inhibits a step in the de 
novo pyrimidine biosynthesis pathway downstream from DHO. 
Together, these results confirm that MEDS433 selectively targets DHODH in HSV-infected 
cells and that the inhibition of DHODH is in charge of the overall anti-HSV activity of 
MEDS433. 
 
3.4 The combination of MEDS433 with an inhibitor of the nucleoside salvage pathway 
enhances the antiviral activity 
Despite useful in confirming the molecular target of MEDS433, the observation that 
uridine reversed the anti-HSV activity of MEDS433 may lead to hypothesize that, in the 
presence of physiological concentration of uridine as that occurring in vivo, the pyrimidine 
salvage pathway may reduce the antiviral efficacy of a DHODH inhibitor by importing 
extracellular nucleosides. To tackle this problem, we explored the effects of a combination 
treatment of MEDS433 with an inhibitor of the nucleoside transport, such as dipyridamole 
(DPY). To this end, a checkerboard analysis of MEDS433-DPY combination was carried 









even with 20 μM uridine to exceed physiological plasma conditions (Pizzorno, et al. 2002). 
As depicted in Fig. 6A, the presence of 20 μM exogenous uridine abrogated, as expected, 
the inhibitory activity of MEDS433 at concentrations reducing HSV replication by 65 - 90% 
when it was tested as single agent (Fig. 2). In contrast, when the same MEDS433 
concentrations were examined in the presence of increasing amounts of dipyridamole, the 
combination of the two molecules successfully reduced HSV-1 replication despite the 
presence of exogenous uridine (Fig. 6A). At the used concentrations, DPY by itself did not 
exerted an inhibitory activity on HSV replication (data not shown), in accord to previous 
observations (Snoeck et al., 1994). Furthermore, the DPY-mediated enhancement of 
MEDS433 antiviral activity was not due to an aspecific cytotoxic effect, since none of the 
tested combinations affected Vero cell viability (Fig. 6B). 
Taken together, these results sustain the feasibility of a combination of a DHODH inhibitor 
and a pyrimidine salvage inhibitor to determine an anti-HSV activity even in the presence 
of uridine concentrations that even exceed in vivo host conditions. 
 
3.5 The combination of MEDS433, acyclovir and dipyridamole results in a synergistic 
effect on HSV-1 replication  
 Lastly, we investigated whether the antiviral activity of MEDS433 and the reference 
drug acyclovir would result in a synergistic, additive or antagonistic effect when tested in 
combination. To this end, the combined effects of 0.25-, 0.5-, 1-, 2-, or 4-fold of MEDS433 
EC50 to ACV EC50 ratio were assessed by plaque reduction assays and then analyzed 
using the CompuSyn software. Results of MEDS433-ACV combinations are represented in 
Fig. 7A as a fractional effect analysis (Fa) plot in relation to the concentrations of drugs 
used, where Fa values closer to 1 indicate greater antiviral activity. The anti-HSV efficacy 
of ACV was clearly increased by the combination with MED433 as shown by the Fa values 









(Fig. 7A). The EC50 of ACV (0.330 μM) was in fact decreased to 0.128 μM by the 
combination with MEDS433 (Fig. 7A). The calculated Combination Index (CI) values then 
indicated that combination of MEDS433 with ACV resulted in a synergistic effect at any of 
drug combinations tested, since all the CIs were < 0.9 (Table 3) (Chou, 2006).  
Then, to evaluate the efficacy of the MEDS433-ACV combination in the context of the 
inhibition of the pyrimidine salvage pathway, as that determined by DPY, the anti-HSV 
activity of the combination of the different MEDS433 EC50 to ACV EC50 relative rates was 
measured in the presence of 3 μM DPY. As shown in Fig. 7A and Table 3, the antiviral 
strength of the MEDS433-ACV combination was further increased by the addition DPY, 
since Fa values of the triple combination (orange hexagons) were even more close to 1 
than those of the MEDS433-ACV combination, and the EC50 of ACV further reduced to 
0.089 μM. Furthermore, none of the MEDS433-ACV or MEDS433-ACV-DPY combinations 
exhibited significant cytotoxic effects against Vero cells (Fig. 7B), thus indicating that their 
synergistic anti-HSV activity was not the result of an increased cytotoxicity, which would 
have prevented the virus from replicating, but that it derived from the combined 
interference of different targets and mechanisms of action.  
These results suggest that both combinations of MEDS433 and ACV and MEDS433, ACV 
and DPY might represent a new pharmacological strategy to be considered for the 
management of HSV infections. 
 
4. Discussion 
This study shows that the small molecule MEDS433 exerts a potent dose-dependent 
antiviral activity against clinical isolates of HSV-1 and HSV-2 with a mechanism that stems 
from the inhibition of the de novo synthesis of pyrimidines. 
In a previous study, MEDS433 was shown to inhibit hDHODH activity with a potency 









myeloid differentiation in AML cell lines at concentrations one log digit lower than those of 
brequinar (Sainas et al., 2018). Crystallographic studies of MEDS433 in complex with 
hDHODH then showed that it has a binding mode similar to that of brequinar, inside the 
ubiquinone binding site of the enzyme (Sainas et al., 2018).  
Here, we have observed that even when tested for anti-HSV activity, MEDS433 results 
more active than brequinar and all other derivatives examined (Fig. 1). Among the tested 
hDHODH inhibitors, MEDS433 is in fact characterized by the highest inhibitory potency 
against hDHODH (IC50 1.2 nM) and a favorable lipophilicity with a logD
7.4 value of 2.35 
(Table 1). To this regard, a logD7.4 value of 2.50 has been suggested for optimal inhibition 
of mitochondrial DHODH, since inhibitors with lower logD7.4 are disadvantaged in reaching 
the mitochondrial membrane, while higher logD7.4 values may reduce their cellular 
adsorption (Gradl et al., 2019). It is therefore reasonable that MEDS433 was more active 
as anti-HSV agent than either the most polar (low logD values) brequinar, 2, 6, and 8 
compounds, or the most lipophilic 5 and 7 derivatives (logD7.4 3.27 and 3.28, respectively).  
Under normal physiological conditions, cells fulfill their requirement of pyrimidines 
mainly through the salvage pathways, therefore recycling pre-existing nucleosides from 
both degradation of intracellular nucleic acids and uptake of extracellular nucleosides. In 
contrast, in highly metabolically active virus-infected cells, the exceptional need for large 
pyrimidines pools associated to rapid viral replication cannot be supply sufficiently by 
nucleotide recycling. To keep up with the pyrimidine demand in infected cells, in fact, 
herpesviruses activate both the de novo pyrimidine biosynthetic gene expression and the 
metabolic flux to UTP (Gribaudo et al., 2002; Munger et al., 2008). It is therefore 
reasonable that de novo pyrimidine biosynthesis rather than its salvage pathway is more 
critical for herpesvirus replication, effectively making the rate-limiting DHODH enzyme 









The observation that HSV replication was largely restricted when the DHODH activity was 
inhibited therefore confirms the dependence of HSV on the host de novo pyrimidine 
biosynthesis for efficient replication, albeit, given the premises summarized above, this 
finding is not unexpected. In addition to this, with regard to herpesviruses infections, it has 
already been observed that a DHODH inhibitor can potently block the replication of the 
Human Cytomegalovirus (HCMV) with an in vitro EC50 of 0.78 µM (Marschall et al., 2013). 
However, the present study is the first to report the antiviral efficacy of a low cell toxicity 
hDHODH inhibitor against HSV-1 and HSV-2 with a potency at least comparable to that of 
the reference drug acyclovir, thus suggesting that inhibition of DHODH activity by 
MEDS433 results in the reduction in the production of pyrimidines at an extent that 
restricts HSV replication but not cell growth. 
However, it is worth noting that our study adds two new pieces of knowledge to the field 
of HTAs targeting the replenishment of nucleotides in virus-infected cells, that may be of 
interest to be considered to design new strategies for the management of HSV infections. 
The first consists in the observation of the efficacy of a combined treatment between an 
inhibitor of the de novo pyrimidine biosynthesis, MEDS433, and dipyridamole, a broad 
nucleoside transporter inhibitor that blocks the nucleoside salvage from extracellular 
environment (Fitzgerald, 1987). In fact, when DPY was combined with concentrations of 
MEDS433 no longer effective against HSV due to the presence of extracellular uridine 
which mimics the physiological conditions in the infected host, it restored the antiviral 
activity of the hDHODH inhibitor. This observation is relevant as there is experimental 
evidence of the absence of inhibitory effects of pyrimidine biosynthesis inhibitors on the 
growth of some RNA viruses, in both rodents and non-human primate models despite their 
high efficacy in vitro, and likely due to the systemic pyrimidine salvage pathway that by 
importing extracellular nucleosides into virus-infected cells, may compensate DHODH 









While the combination of DPY with inhibitors of de novo pyrimidine biosynthesis has been 
investigated previously in both in vitro studies and clinical trials to increase the anticancer 
effects of the latter, the potential of this combination against virus infections has not yet 
been thoroughly investigated. To this regard, it has been reported very recently the 
efficacy of a combination of a hDHODH inhibitor, GSK983, with a pyrimidine salvage 
inhibitor such as the cyclopentenyl uracil (CPU) in suppressing the in vitro replication of 
dengue virus, even in the presence of physiological concentrations of uridine (Liu et al., 
2020). CPU is a uridine analogue able to block the activity of uridine/cytidine kinase 2 
(Cysyk et., 1995), a cellular enzyme that phosphorylates uridine to UMP in the pyrimidine 
ribonucleotide salvage pathway, and therefore acting at a stage downstream from that 
targeted by DPY (Fitzgerald, 1987).  DPY in fact is a pyrimido-pyrimidine derivative widely 
used as an oral agent in the prophylaxis of thromboembolism in cardiovascular disease, 
because of its platelet antiaggregant and vasodilator activities due to the inhibition of the 
uptake of adenosine into platelets, endothelial cells and erythrocytes (Fitzgerald, 1987; 
Schaper, 2005). These cellular effects have been observed even after a single DPY dose 
at which the measured Cmax was of 2.2 μg/ml, corresponding to 4.4 μM (Gregov et al., 
1987). This value is greater than the highest DPY concentration observed to be effective in 
combination with either MEDS433 (Fig. 6A) or MEDS433 and ACV (Fig. 7A), that therefore 
it could be clinically achievable in patients treated with DPY. The wide clinical experience 
of DPY could thus allow its rapid repositioning against viruses to be clinically useful in 
combination with HTAs and/or direct acting antivirals. 
The second finding which deserves a further comment is the observation that several 
combinations of MEDS433 and ACV interact in a synergistic manner, each reinforcing the 
other’s antiviral activity against HSV-1. To our knowledge, this is the first observation of a 
synergistic effect between a direct acting antiviral agent used to treat infections caused by 









Junín virus that causes the Argentine hemorrhagic fever, it has been reported that the 
combination of A771726, the active metabolite of the hDHODH inhibitor leflunomide 
approved by FDA for treatment of rheumatoid arthritis and autoimmune disorders (Sanders 
and Harisdangkul, 2002), and ribavirin showed a significantly more potent antiviral activity 
than each single drug treatment (Sepulveda et al., 2018).  
Relevant to the possibility to exploit combinations between direct-acting antivirals and 
agents targeting the pyrimidine pathway against HSV infections, it is possible to have in 
view a regimen based on three different molecules: ACV, a DHODH inhibitor, and DPY. As 
we have observed in this study, indeed DPY not only restores the antiviral efficacy of the 
DHODH inhibitor that could be abolished by the uptake of exogenous pyrimidines from the 
bloodstream (Fig. 6A), but it also strengthens the synergism between ACV and MEDS433 
against HSV replication (fig. 7A).  Obviously, one could argue that the addition of DPY to 
an ACV-DHODH combination could reduce the synergistic effect in vivo due to the 
inhibition of nucleoside transport and thus impairing the uptake of ACV from bloodstream. 
However, this would not seem to be the case, as it has been observed that DPY does not 
compromise the transport of ACV into cells (Mahony et al., 1988), as well as that of others 
nucleoside analogs, such as AZT and ddC (Szebeni et al., 1989). Therefore, our findings 
along with the reported ability of DPY to inhibit the intracellular transport of thymidine and 
dCTP which could compete with ACV for viral kinase-mediated phosphorylation, suggest 
that DPY actually may potentiate the antiviral efficacy of ACV. Although future 
investigations in animal models of HSV infection will be required to validate the in vitro 
observations, our results suggest that combinations of ACV and MEDS433 or ACV, 
MEDS433 and DPY might represent a new therapeutic strategy for HSV infections. 
In conclusion, the results of this study suggest MEDS433 as an attractive candidate as 
a novel HTA that might show advantageous features, such as an antiviral activity against a 









against respiratory viruses, such as Influenza virus, Respiratory Syncytial Virus, and 
SARS-CoV-2 (unpublished results), and the low risk of emergence of drug-resistant 
strains. 
Moreover, MEDS433 could also be considered for combinatorial drug treatment with 
nucleoside analogues and other anti-pyrimidines, such as ACV and DPY, for the 
therapeutic management of HSV infection. In light of the fact that no new anti-HSV agents 
have been introduced in nearly three decades, the potent in vitro anti-HSV activity of 
MEDS433 calls for further studies to be performed to evaluate their efficacy and safety in 
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Figure 1.  Identification of hDHODH inhibitors with anti-HSV activity . Vero cells were 
pretreated and treated with 0.5 μM of the different DHODH inhibitors (Table 1) 1 h prior to, 
during infection with HSV-1 AS1 (50 PFU/well), and throughout the experiment. At 48 h 
post-infection, viral plaques were stained and the mean plaque number in treated culture 
determined compared to that of DMSO-treated and mock-infected control monolayers. The 
data shown represent means ± SD (error bars) of three independent experiments 
performed in triplicate. 
Figure 2. Antiviral activity of MEDS433 against HSV -1 and HSV-2. Vero cell 
monolayers were infected with the clinical isolates of HSV-1 AS1 or HSV-2 AS3 at MOIs or 
0.01 or 1, and, where indicated, the cells were treated with increasing concentrations of 
MEDS433 1 h before as well as during virus adsorption. MEDS433 remained in the culture 
medium throughout the experiment, until an extensive viral cytopathic effect was observed 









supernatants of Vero suspensions by standard plaque assay. The number of plaques was 
plotted as a function of MEDS433 and ACV concentrations, and the concentrations 
producing 50% and 90% reductions in plaque formation (EC50 and EC90, respectively) 
were determined. The data shown represent means ± SD (error bars) of three independent 
experiments performed in triplicate. 
Figure 3. MEDS433 inhibits HSV-1 viral DNA synthesi s. Vero cell monolayers were 
infected with the clinical isolate of HSV-1 AS1 at an MOI of 0.1, and, where indicated, the 
cells were treated with 5 μM MEDS433, or 0.02% DMSO as a control. At 4, 8, 16, 24 and 
48 h p.i., total DNA was purified and qPCR was performed with appropriate HSV primers. 
HSV-1 genomic copies were determined by interpolation from the standard curve, 
generated by a serially diluted UL30 plasmid and normalized to the number of cells. The 
data shown are the means ± SD of two independent experiments performed in triplicate 
and analyzed by unpaired t-test. ** (p<0.0001) versus calibrator sample (DMSO).  
Figure 4. MEDS433 reduces the expression of HSV L p roteins. Vero cells were 
infected with HSV-1 AS1 at an MOI of 1, or mock infected (mock) and, where indicated, 
the cells were treated prior to and during infection with 5 μM MEDS433, or 0.02% DMSO 
as a control. Total cell extracts were prepared at the indicated times p.i., fractionated by 
8% SDS-PAGE and analyzed by immunoblotting with anti-HSV ICP27 and anti-HSV ICP5 
mAbs. Tubulin immunodetection was used as internal control.  
Figure 5. Inhibition of HSV replication by MEDS433 is reversed by uridine and orotic 
acid. Vero cell monolayers were treated with 1 μM of MEDS433 in the presence or 
absence of increasing concentrations of uridine (upper panels), dihydroorotic acid or orotic 
acid (lower panels) before and during infection with HSV-1 AS1 (A) or HSV-2 AS3 (B) (50 
PFU/well). Following virus adsorption, cells were incubated in the presence of compounds 
and viral plaques were then stained and were microscopically counted at 48 h p.i.. The 









mean count of the control cultures treated with the DMSO vehicle. The data shown 
represent means ± SD (error bars) of three independent experiments performed in 
triplicate and analyzed by a one-way ANOVA followed by Dunnett’s multiple comparison 
test. ** (p < 0.0001) and * (p < 0.05) compared to the calibrator sample (MEDS433 alone). 
Figure 6. A combination of modulators of pyrimidine  metabolism inhibits HSV 
replication in the presence of exogenous uridine. A ) Vero cell monolayers were treated 
with MEDS433 alone or in combination with different concentrations of DPY before and 
during HSV-1 AS1 infection (50 PFU/well). Following virus adsorption, cell monolayers 
were overlaid with 0.9% methylcellulose in the presence of compounds and viral plaques 
were then stained and counted at 48 h p.i.. In all the assays, culture medium was 
supplemented with 20 μM uridine. The data shown represent means ± SD (error bars) of 
three independent experiments performed in triplicate.  
B) To determine cell viability, Vero cells were exposed to the different concentrations of 
MEDS433 alone or in combination with different amounts of DPY, or vehicle (DMSO), as 
control. After 72 h of incubation, the number of viable cells was determined by the 
CellTiter-Glo Luminescent assay. Results are shown as means ± SD (error bars) of three 
independent experiments performed in triplicate 
Figure 7. Effects of the combination of MEDS433, ac yclovir and dipyridamole on 
HSV replication. A) Plaque reduction assays were performed on Vero cell monolayers 
treated with different concentrations of MEDS433 and ACV as single agents, or in 
combination in the absence or presence of 3 μM of DPY prior to and during HSV-1 AS1 
infection (50 PFU/well). After virus adsorption, cells were incubated in the presence of 
compounds and at 48 h p.i., viral plaques were stained and counted. Plaque numbers 
were analyzed with the CompuSyn software. The effects on HSV-1 replication of 
MEDS433 or ACV used as single agents are depicted by red and black Fa curve, 









indicated by blue triangles and orange hexagons, respectively. The results are 
representative of three independent experiments performed in triplicate.  
B) To determine the cytotoxic effect of combinations, Vero cell monolayers were treated 
with the vehicle (DMSO), or with different concentrations of MEDS433 alone or in 
combination with different concentrations of ACV and in the absence or presence of 3 µM 
of DPY. At 72 h, Vero cell viability was assessed by the CellTiter-Glo Luminescent assay. 


































Table 1. The hDHODH inhibitors investigated as anti-HSV agents in  the study 
 
Structure  Compound Code hDHODH
a 
IC50 ± SE (nM)
 Log D 7.4 ± SDc Reference 
  
Brequinar 1.8 ± 0.3 1.83 ± 0.02 (Peters, 2018) 
  
MEDS433 1.2 ± 0.2 2.35 ± 0.02 (Sainas et al., 2018) 
 
1  





(MEDS604) 6.23 ± 0.63 0.98 ± 0.03 









(MEDS606)  2.75 ± 0.31 2.46 ± 0.04 




(MEDS608) 2.30 ± 0.33 3.27 ± 0.19 




(MEDS610) 150 ± 15 1.84 ± 0.06 























4.09 ± 0.62 3.28 ± 0.12 




(MEDS614) 2.78 ± 0.32 1.82 ± 0.09 
(Sainas et al., 
2021) 
 
aThe inhibitory effect of the compounds (expressed as IC50) on hDHODH in vitro 
assay. 
 
 Table 2. Antiviral activity of MEDS433 against dif ferent HSV strains 
   MOI of 0.01  












aEC50, compound concentration that inhibits 50% of virus replication, as determined by 
VRAs against HSV-1 and HSV-2 in Vero cells. Reported values represent the means ± SD 
of data derived from three experiments in triplicate. 
 
bEC90, compound concentration that inhibits 90% of virus replication, as determined by 
VRAs 
 
cCC50, compound concentration that produces 50% of cytotoxicity, as determined by cell 
viability assays in Vero cells. Reported values represent the means ± SD of data derived 
from three experiments in triplicate. 
 
dSI, selectivity index (determined as the ratio between CC50 and EC50
  
HSV-1 AS1 0.085 ± 0.021 0.765 ± 0.167 234 ± 18.2 2752 
HSV-1 AS2 0.116 ± 0.014 0.678 ± 0.127 234 ± 18.2 2017 
HSV-2 AS3 0.061 ± 0.019 0.840 ± 0.178 234 ± 18.2 3836 
HSV-2 AS4 0.095 ± 0.027 0.778 ± 0.168 234 ± 18.2 2463 
                                                       MOI of 1  
HSV EC50 (μM)a EC90 ( μM)b CC50 (μM)c SId 
HSV-1 AS1 0.078 ± 0.024 0.702 ± 0.111 234 ± 18.2 3000 
 









Table 3. Analysis of the effects of the combination  of MEDS433, ACV and DPY 




aFold of EC50 MED/ EC50 ACV yielding an equipotent concentration ratio (approximately 
1:0.31) between the two combined drugs. The EC50 values was determined by PRAs 
against HSV-1, as described in Material and Method. The ratio of the drugs was 
considered 1:0.31 from Fig.2. 
 
 b Combination Index (CI), extrapolated by computational analysis with the CompuSyn 
software. Reported values represent means ± SD of data derived from n = 3 independent 
experiments in triplicate using MED/ACV concentration ratio showed in a.  
 
c Drug combination effect defined as: very strong synergism for CI<0.1; strong synergism 
for 0.1<CI<0.3; synergism for 0.3<CI<0.7; moderate synergism for 0.7<CI<0.85, according 
to Chou, 2006. 
 
d Combination Index (CI), extrapolated by computational analysis with the CompuSyn 
software. Reported values represent means ± SD of data derived from n = 3 independent 
experiments in triplicate using MED/ACV concentration ratio showed in a  added with 3 μM 


























+ 3 μM DPYc 
4x 0.156 ±0.051 Strong synergism  0.156 ±0.096 
Strong 
synergism 
2x 0.082 ± 0.001 Very strong synergism  0.078 ± 0.033 
Very strong 
synergism 
1x 0.334 ± 0.039 Synergism  0.162 ± 0.043 Strong synergism 
0.5x 0.419 ± 0.042 Synergism  0.299 ± 0.017 Strong synergism 
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• We characterize the anti-HSV activity of the new DHODH inhibitor MEDS433 that 
targets the de novo pyrimidine biosynthesis 
• MEDS433 impairs the in vitro replication of HSV-1 and HSV-2 in the nanomolar range  
• The anti-HSV activity of MEDS433 is reversed by uracil and orotic acid confirming that it 
derives from inhibition of DHODH 
• The simultaneous treatment with MEDS433 and acyclovir potentiates the anti-HSV 
activity of the combination  
• MEDS433 differs from current anti-HSV drugs, and may represents a promising 
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